TABLE 1.
Determination of the PD50 of v2RVFH in African cattlea
| Vaccine | Dose | No. of cattle/no. tested
|
||
|---|---|---|---|---|
| Clinical response to vaccination | Clinical response to challengeb | Survival | ||
| v2RVFH | 102 PFU | 0/4 | 2/4 | 3/4 |
| v2RVFH | 103 PFU | 0/4 | 0/4 | 4/4 |
| v2RVFH | 104 PFU | 0/4 | 0/4 | 4/4 |
| v2RVFH | 105 PFU | 0/4 | 0/4 | 4/4 |
| v2RVFH | 106 PFU | 0/3 | 0/3 | 3/3 |
| v2RVFH | 108 PFU | 0/3 | 0/3 | 3/3 |
| PTCV | 3.2 × 102 TCID50 | 0/2 | 0/2 | 2/2 |
| Control | NAc | NA | 2/2 | 0/2 |
a
v2RVFH was given intramuscularly and PTCV was given subcutaneously. Controls (sentinels) are naive cattle housed together with animals that received 108 PFU of v2RVFH.
b
No. of cattle with fever, congestion, and mouth lesions. Animals were challenged 28 days postvaccination with RPV.
c
NA, not applicable.